Bill B. Messer, M.D., Ph.D.
- Associate Professor of Molecular Microbiology and Immunology, School of Medicine
- Associate Professor of Medicine, Division of Infectious Diseases, School of Medicine
- Molecular Microbiology and Immunology Graduate Program, School of Medicine
- Program in Molecular and Cellular Biosciences, School of Medicine
Biography
Dr. Messer completed his Ph.D. in ecology in 2003 under the mentorship of Dr. Tom Whitmore in the Department of Geography and in the lab of Dr. Aravinda de Silva in the Department of Microbiology and Immunology at UNC Chapel Hill. His dissertation focused on the evolution of dengue virus serotype 3 and the emergence of dengue hemorrhagic fever in Sri Lanka. After completing his M.D. and residency and his residency in internal medicine at UNC in 2008, he joined the lab of Dr. Ralph Baric where he took primary responsibility for the dengue virus research program, supported by the Southeast Regional Center for Excellence in Biodefense. In May, 2012, following completion of his fellowship in infectious diseases, Dr. Messer was appointed clinical assistant professor in the Department of Medicine in the UNC School of Medicine. In November, 2012, Dr. Messer joined the faculty in the departments of medicine and molecular microbiology and immunology at Oregon Health & Sciences University as an assistant professor where he continues to study dengue virus genetics.
Education and training
-
Degrees
- M.D., 2006, University of North Carolina at Chapel Hill School of Medicine
- Ph.D., 2003, University of North Carolina at Chapel Hill
-
Residency
- Internal medicine, University of North Carolina Hospitals, Chapel Hill, NC, 2009
-
Fellowship
- Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, 2012
-
Certifications
- American Board of Internal Medicine, Internal Medicine, 2010
- American Board of Internal Medicine, Infectious Diseases, 2011
Memberships and associations:
- American College of Physicians
Additional information
Publications
Elsevier pure profilePublications
Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen
Journal of Clinical InvestigationExtreme γ′ fibrinogen levels in COVID-19 patients
Blood Cells, Molecules, and DiseasesFeatures of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes
Nature communicationsIgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
Nature communicationsPreventing unnecessary urine cultures at a Veteran's affairs healthcare system
Infection control and hospital epidemiologyThe Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection
VaccinesA Maximum Entropy Model of the Distribution of Dengue Serotype in Mexico
Transboundary and Emerging DiseasesAn extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants
JCI InsightInfection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein
PLoS neglected tropical diseasesMulti-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
Cell Reports MedicineRelationship of Heterologous Virus Responses and Outcomes in Hospitalized COVID-19 Patients
Journal of ImmunologyA lyophilized colorimetric RT-LAMP test kit for rapid, low-cost, at-home molecular testing of SARS-CoV-2 and other pathogens
Scientific ReportsBimodal distribution pattern associated with the PCR cycle threshold (Ct) and implications in COVID-19 infections
Scientific ReportsBNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age
Cell ReportsCase Report
Infectious Diseases in Clinical PracticeCase Report
Frontiers in NeurologyDevelopment and Validation of an Enzyme Immunoassay for Detection and Quantification of SARS-CoV-2 Salivary IgA and IgG
Journal of ImmunologyPhenotypes of disease severity in a cohort of hospitalized COVID-19 patients
EBioMedicineSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Memory B Cells from Individuals with Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern
Journal of Infectious DiseasesVaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
Science ImmunologyAdapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections
Frontiers in immunologyCellular and humoral immune responses in mice immunized with vaccinia virus expressing the sars-cov-2 spike protein
Journal of ImmunologyClinical symptoms of dengue infection among patients from a non-endemic area and potential for a predictive model
American Journal of Tropical Medicine and HygieneCross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
Cell ReportsEstablishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings
Open Forum Infectious DiseasesIdentification of SARS-CoV-2 RNA in healthcare heating, ventilation, and air conditioning units
Indoor Air